KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Short-term Investments (2016 - 2026)

Alnylam Pharmaceuticals filings provide 18 years of Short-term Investments readings, the most recent being $1.3 billion for Q1 2026.

  • On a quarterly basis, Short-term Investments rose 17933.94% to $1.3 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $1.3 billion, a 17933.94% increase, with the full-year FY2025 number at $1.3 billion, up 15241.27% from a year prior.
  • Short-term Investments hit $1.3 billion in Q1 2026 for Alnylam Pharmaceuticals, up from $1.3 billion in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $1.7 billion in Q2 2025 to a low of $7.2 million in Q1 2025.
  • Median Short-term Investments over the past 5 years was $1.3 billion (2026), compared with a mean of $1.0 billion.
  • Biggest five-year swings in Short-term Investments: plummeted 99.57% in 2025 and later skyrocketed 17933.94% in 2026.
  • Alnylam Pharmaceuticals' Short-term Investments stood at $28.1 million in 2022, then surged by 5644.67% to $1.6 billion in 2023, then crashed by 99.5% to $8.2 million in 2024, then soared by 15241.27% to $1.3 billion in 2025, then rose by 3.77% to $1.3 billion in 2026.
  • The last three reported values for Short-term Investments were $1.3 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.2 billion (Q3 2025) per Business Quant data.